Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday
2025-10-30 17:17:00 ET
Healthcare diagnostics product supplier Bio-Rad Laboratories (NYSE: BIO) notched twin beats in its just-released third quarter, but that wasn't enough for a choosy stock market. Investors sold out of the company's shares in the wake of that earnings report to leave it with an over 3% loss on Thursday. This was a steeper fall than the 0.9% decline of the benchmark S&P 500 index.
Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles ( GAAP ) rose at a slightly higher rate, advancing by 8% to just under $61 million. On a per-share basis, that non-GAAP (adjusted) bottom line figure was $2.26.
Image source: Getty Images.
NASDAQ: BIO
BIO Trading
9.62% G/L:
$272.74 Last:
322,349 Volume:
$274.72 Open:
